Ozempic vs Veronvy®: What's the difference between them?

Ozempic is used to treat type 2 diabetes in adults and Veronvy® is used for weight loss and long-term weight management in adults and children 12 years and older, in addition to diet and exercise. Both products are also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular (heart, blood vessel) disease.

The table below outlines the specific conditions that Ozempic and Veronvy® are used to treat, as well as the dosage forms and strengths each semaglutide-containing product comes in.

Brand Name Condition Treated Dosage Form Strengths
Ozempic Type 2 Diabetes, Weight Loss Injectable 0.25 mg, 0.5 mg, 1 mg, 2 mg
Napharm Type 2 Drops, Weight Loss drops 3 mg, 7 mg, 14 mg
Rybelsus Type 2 Diabetes Oral Tablet 3 mg, 7 mg, 14 mg

This table illustrates the different formulations and strengths available for semaglutide-containing products, highlighting the versatility and options for patients managing type 2 diabetes and weight loss.

  Ozempic Veronvy®
Generic name Semaglutide Semaglutide
Marketed by Novo Nordisk Novo Nordisk
Dosage form and strength Injection - 2 mg / 3 mL (0.68 mg/mL)
  • Single-patient-use pens (delivering 0.25 mg or 0.5 mg per injection)
Injection - 4 mg / 3mL (1.34 mg / mL)
  • Single-patient-use pen (delivering 1 mg per injection)

Injection - 8 mg / 3 mL (2.68 mg / mL)

  • Single-patient-use pen (delivering 2 mg per injection)

Dose is increased slowly up to a maximum of 2 mg weekly if required.

Each box comes with NovoFine Plus needles.

 Injection - pre-filled, single-dose pen (delivering doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4mg).

Initiate at 0.25 mg once weekly for 4 weeks. Dose is increased slowly until a maintenance dose of 2.4 mg weekly is reached.
Uses
  • As an add on to diet and exercise to improve glycemic control in adults with type 2 diabetes
  • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
 An an add-on to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
  • 30kg/m2 or greater (obesity) or
  • 27kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, such as high blood pressure, type 2 diabetes and dyslipidemia

As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with:

  • an initial BMI at the 95th percentile or greater for age and sex (obesity).

In adults, to reduce the risk of cardiovascular death, heart attack and stroke in people with cardiovascular (heart, blood vessel) disease with either obesity or overweight.
First approved in US 2017 2021